Hints and tips:
...Analysts with Barclays note that roughly a dozen biotechs have key catalysts before year end, including data from trials undertaken by Gilead, Biogen Idec, Neurocrine Biosciences and Alexion Pharmaceuticals...
...MS pills from Novartis and Biogen Idec have combined sales that will pass $6bn this year, and Ozanimod appears (at this early date) to have fewer side-effects than either....
...Big companies with lots of biotech experience — Amgen, Pfizer, Biogen Idec — are committing piles of capital to biosimilars....
...Roche, Johnson & Johnson and Biogen Idec were among drugmakers to announce tie-ups on Monday, a day after Shire agreed to buy NPS Pharmaceuticals for $5.2bn....
...Biogen Idec led the US benchmark index after the biotechnology company said its experimental drug to treat Alzheimer’s showed promise in an early-stage trial and that it would now be moved to phase 3 trials...
...US investment bank JPMorgan will help set up the fund, with GlaxoSmithKline, Johnson & Johnson, Pfizer, Eli Lilly and Biogen Idec among the companies committing money alongside the UK government....
...“Companies with strong emphasis on biotech such as Roche and Biogen Idec still have the greatest protection from patent exposure but competition from biosimilars will gradually increase,” he added....
...Shares of drugmaker Biogen Idec declined 1 per cent to $337.77 after analysts at Nomura downgraded the stock to “neutral” from “buy” and lowered their price target to $378 from $407....
...Google announced this week a collaboration with Biogen Idec, the US biotech company, to study environmental and biological factors that might accelerate or slow multiple sclerosis advancing....
...Market valuations of three stalwarts of the industry — Biogen Idec, Gilead and Regeneron — have more than doubled over the past two years....
...Some of Ms Yellen’s targets are on the list: Celgene, Netflix, Facebook, Biogen Idec. But is Goodyear Tire an emblem of the new economy?...
...Mr Ornskov says he is eyeing further deals in his quest to match the success of US biotech companies such as Gilead Sciences and Biogen Idec which have broken into the ranks of big pharma....
...Whereas the US has nurtured a cadre of biotech powerhouses such as Amgen, Biogen Idec and Gilead Sciences that are shaking up the traditional pharmaceuticals industry, Europe has few such examples....
...Advate’s franchise is threatened, however, by “long-acting” agents, from competitors Biogen Idec and Novo Nordisk, which can be taken less frequently....
...Biogen Idec, Novo Nordisk and Gilead trade at sportier multiples of earnings than the others, because of the higher growth targets analysts are pencilling in. Then there is Bristol-Myers Squibb....
...Royalty Pharma, a specialist private equity company, for example, has bought royalties for drugs marketed by companies including Amgen, Biogen Idec and Johnson & Johnson....
...Others such as Biogen Idec have also produced huge returns for early investors as breakthrough drugs have catapulted them into the realm of big pharma....
...Idec and Gilead Sciences if it remained independent....
...Gilead was up 0.08 per cent to $72.13, Biogen Idec fell 1.86 per cent to $312.60, Amgen dropped 1.34 per cent to $121.28 and Celgene shed just over 2 per cent to finish at $141.48....
...Idec earlier this year....
...The day’s losses extended across the large-cap biotech sector as Biogen Idec fell 8.2 per cent to $318.53, Celgene dropped 3.7 per cent to $144.40 and Amgen lost 3.2 per cent to $122.93....
...Investors have been attracted to the biotech sector by a fresh wave of scientific innovation and hopes that some of the latest market entrants can emulate the success of companies such as Biogen Idec, Gilead...
...Healthcare was one of the strongest sectors of the S&P 500 on the week, up 1.6 per cent, after biotechnology company Biogen Idec rose 16.5 per cent to $285.62....
...The takeover battle, triggered after Elan earlier this year sold its multiple sclerosis drug Tysabri to its partner Biogen Idec, has been marked by aggressive rhetoric on both sides, while drawing in others...
...Elan’s own management has claimed the company is worth up to $20.80 a share, based on forecasts of future earnings from Tysabri, the multiple sclerosis drug it sold to its partner Biogen Idec....
International Edition